Travere Therapeutics logo

Travere Therapeutics

TVTX | NASDAQ
Chart Builder DCF Calculator
$49.70
-$0.95 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$49.50
-$0.20 (-0.40%)
After-hours: Nov 16, 2026, 7:46 PM ET
-1.88%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
49.3
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #297/1021 (Top 29%)

Key Statistics

Market Data

Market Cap $4.77B
1D Range
49.28 51.00
52W Range
26.79 67.52

Valuation (TTM)

PE -31.86
PB 211.25
EV/EBITDA -50.12

Valuation (NTM)

Forward PE 18.08
Forward PEG -0.24
Price Target $74.00
Loading financial charts...

Profile

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppre...

Sector Healthcare
Industry Biotechnology
Employees 497
IPO Date Nov 8, 2012
Fiscal Year January - December

Latest News

Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

12 hours ago · seekingalpha.com

Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy

17 hours ago · seekingalpha.com

Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy
Travere Therapeutics to Participate at Upcoming Investor Conferences

13 days ago · businesswire.com

Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings

14 days ago · zacks.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

14 days ago · marketbeat.com

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

14 days ago · zacks.com

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics Reports Third Quarter 2026 Financial Results

14 days ago · businesswire.com

Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics to Report Third Quarter 2026 Financial Results

21 days ago · businesswire.com

Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

24 days ago · businesswire.com

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Earnings

Latest Earnings
Nov 2, 2026
EPS
-$0.55
Miss -891.88%
REV
$224.56M
Beat +14.99%
Next Earnings
Feb 18, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$74.00
Upside
+48.89%
Buy (10)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.